Background and Objective: Vancomycin is frequently the antibiotic of choice for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). For the last years, the incidence of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) has been increased in various parts of the world. The present study ...

vancomycin susceptibility of methicillin-resistant staphylococcus aureus has been changed over time and its average minimum inhibitory concentration increased from 1.5 to 1.75 mg/l. a recently published guideline by the american society of health pharmacist recommended a daily dose of 15-20 mg/kg every 8 to 12 hours of vancomycin to achieve a trough concentration between 15-20 mg/l for treatmen...

BACKGROUND Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancom...

BACKGROUND Vancomycin is used abundantly in patients undergoing HSCT, especially during neutropenic fever. Despite its widespread use little is known about vancomycin pharmacokinetics in HSCT patients. We conducted this study to investigate vancomycin pharmacokinetic parameters in our HSCT patients and to evaluate current dosing regimen based on trough vancomycin concentrations measurement. M...

This study investigated the efficacy of co-deposited vancomycin/chitosan coatings prepared using a plasma process on metallic implants in bacterially challenged rabbit model. A BioDepTM coating was used to deposit thin layers chitosan with vancomycin onto titanium alloy surfaces. Coated were examined standard microscopy, profilometry and elution studies. Nitrided Ti-6Al-4V (Ti alloy) dynamic co...

In order to investigate the effect of pharmacist intervention on vancomycin use, this study was performed on all patients receiving vancomycin in the intensive care unit (ICU) and hematology-oncology ward of Taleghani Educational Hospital in Tehran, Iran. Vancomycin use was assessed during a pre- and post-intervention period in accordance with the Center of Disease Control and prevention (CDC) ...

INTRODUCTION Methicillin-resistant S. aureus (MRSA) is a common cause of bone and joint infection. BT2-peg2-vancomycin is an investigational bone-targeted formulation of vancomycin which we hypothesized would have increased antimicrobial activity compared to conventional vancomycin in a chronic experimental MRSA osteomyelitis model. METHODS We tested bone affinity using an hydroxyapatite (HA)...

Heterogeneous resistance to vancomycin is thought to precede emergence of intermediate susceptibility to vancomycin in Staphylococcus aureus, but the clinical significance of heterogeneous resistance is unknown. Paired S. aureus isolates from a patient with endocarditis who relapsed after vancomycin treatment were tested for heterogeneous resistance to vancomycin. The pretreatment and the relap...

We attempted to find a relationship between the microbiological properties of bloodstream isolates of methicillin-resistant Staphylococcus aureus (MRSA) and the efficacy of vancomycin in the treatment of bacteremia. Vancomycin susceptibility testing was performed, and bactericidal activity was determined for 30 isolates from 30 different patients with MRSA bacteremia for whom clinical and micro...